June 19th @ 10 am Eastern Most who particpate in AnCan's programs know we are massive proponents of involving palliative care, or as UCSF calls it 'Symptom Management'', early in your treatment path - so we stronlgly recommend attending this CureTalk webinar. Dr. Mike is a good friend of AnCan, as is CureTalk - so […]
TO WATCH THIS WEBINAR, PLEASE CLICK HERE. Do you have biologic kids? Are you living with a chronic and serious condition that could impact your children? Have you ever spoken to them about this? If you answered YES, to the […]
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
This group is for men with complex disease either at diagnosis, or whose disease has recurred with or without evidence of metastasis. With men who have experienced the gamut of treatments, we discuss status, as well as new developments in treatment and technology. New participants are given priority to discuss their situation. 1st & 3rd Mondays […]
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
FOR A RECORDING OF THE WEBINAR, PLEASE CLICK ON THIS LINK: https://youtu.be/vMIGcVsMBEY MORE INFORMATION ON OUR TWICE MONTHLY MS VIDEO CHAT VIRTUAL SUPPORT GROUP CAN BE FOUND AT: https://ancan.org/multiplesclerosis/ TO SIGN UP FOR A REMINDER BEFORE EACH SUPPORT GROUP, […]
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Episode 1 of 3 in Your Prostate Cancer Questions Answered. In 2018, patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) were watching and waiting. Two years later there are three novel androgen receptor inhibitors available. But more options mean more questions for doctors and for patients. In this first installment of our prostate cancer Answers Now series, we’ll explore these […]
Episode 2 of 3 in Your Prostate Cancer Questions Answered In this edition of our prostate cancer Answers Now series, we’ll learn about the latest in testing and imaging for prostate cancer with hosts & AnCan Prostate Cancer Moderators, Len Sierra and Peter Kafka. They will be joined by Scott Tagawa, MD, Professor of Medicine and Urology at NewYork-Presbyterian-Weill Cornell […]
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Episode 3 of 3 in Your Prostate Cancer Questions Answered. Talking honestly about one’s medical realities in the doctor’s office takes practice, but it is a crucial step to take. Tune in as experts discuss how transparent doctor-patient relationships can improve prostate cancer outcomes. Join us for the final segment of our prostate cancer Answers Now series, […]
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
